Back to Search
CHARLES RANKIN, DMD
DMD
Endodontics
NPI: 1235273244Individual
Specialties, Licenses & Credentials
EndodonticsPrimary
Dentist — Endodontics
Code: 1223E0200X
3015(NH)
Research & Publications (20)
Essential role of SBP-1 activation in oxygen deprivation induced lipid accumulation and increase in body width/length ratio in Caenorhabditis elegans.
PMID 19187779·FEBS Lett·2009
7-preclinical
Behavioral and genetic characterization of habituation using Caenorhabditis elegans.
PMID 18771741·Neurobiol Learn Mem·2009
6-review
Habituation revisited: an updated and revised description of the behavioral characteristics of habituation.
PMID 18854219·Neurobiol Learn Mem·2009
6-review
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).
PMID 18941712·Invest New Drugs·2009
3-trial
Introduction to special issue of neurobiology of learning and memory on habituation.
PMID 18929675·Neurobiol Learn Mem·2009
7-preclinical
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
PMID 18235122·J Clin Oncol·2008
3-trial
Effects of developmental exposure to ethanol on Caenorhabditis elegans.
PMID 18336629·Alcohol Clin Exp Res·2008
7-preclinical
External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial.
PMID 18521920·Cancer·2008
3-trial
Pre-assembled tau filaments phosphorylated by GSK-3b form large tangle-like structures.
PMID 18588978·Neurobiol Dis·2008
8-other
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
PMID 18955451·J Clin Oncol·2008
3-trial
A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149).
PMID 18175205·J Neurooncol·2008
3-trial
Behavioral Plasticity in the C. elegans Mechanosensory Circuit.
PMID 19012160·J Neurogenet·2008
6-review
Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization.
PMID 18177741·Adv Enzyme Regul·2008
4-observational
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
PMID 18006112·Lung Cancer·2008
3-trial
Dopamine mediates context-dependent modulation of sensory plasticity in C. elegans.
PMID 17698017·Neuron·2007
7-preclinical
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
PMID 17875730·Cancer Res·2007
7-preclinical
Polarization and local reactivity on organic ferroelectric surfaces: ferroelectric nanolithography using poly(vinylidene fluoride).
PMID 19206654·ACS Nano·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 6 LOUDON RD STE 6
CONCORD, NH 03301 - Phone
- (603) 224-5553
Quick Facts
- NPI
- 1235273244
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile